Table 2.
Objective Response and Progression-Free Survival by MET Genomic Aberrations.
| Factors | N (%) | Responses (ORR %) | P value | 95% CI | PFS (months) | P value | HR | 95% CI | |
|---|---|---|---|---|---|---|---|---|---|
| MET Zygosity | WT Copies | 23 (31%) | 7 (30%) | 0.88 | 15% to 51% | 7.9 | 0.84 | ||
| CN LOH | 24 (32%) | 9 (38%) | 21% to 57% | 7.2 | |||||
| Heterozygous loss | 5 (7%) | 1 (20%) | 2% to 64% | 9 | |||||
| Amplification | 9 (12%) | 3 (33%) | 12% to 65% | 6.5 | |||||
| NE | 14 (19%) | ||||||||
| Whole Genome Duplication (WGD) | Yes | 17 (23%) | 9 (53%) | 0.14 | 31% to 74% | 7.3 | 0.66 | 1.2 | 0.6 to 2.3 |
| No | 50 (67%) | 15 (30%) | 19% to 44% | 8.8 | |||||
| NE | 8 (11%) | ||||||||
| MET Clonality | Subclonal | 2 (3%) | 0 (0%) | 0.5 | 0% to 71% | 4.5 | 0.1 | 2.0 | 0.5 to 8.2 |
| Clonal | 43 (57%) | 19 (44%) | 30% to 59% | 8.9 | |||||
| NE | 30 (40%) | ||||||||
| MET Focality | Broad | 2 (3%) | 1 (50%) | 1.00 | 9% to 91% | 11.0 | 0.51 | 0.6 | 0.1 to 3.3 |
| Focal | 7 (9%) | 2 (29%) | 8% to 65% | 5.5 | |||||
| MET non-amplified§ | 65 (87%) | ||||||||
| NE | 1 (10%) | ||||||||
| Tumor Mutational Burden (TMB) | ≥4.5 mut/Mb | 33 (44%) | 14 (42%) | 0.44 | 27% to 59% | 7.4 | 0.80 | 0.9 | 0.5 to 1.7 |
| <4.5 mut/Mb | 33 (44%) | 10 (30%) | 17% to 47% | 7.2 | |||||
| NE | 9 (12%) | ||||||||
Percentages may not add up to 100% due to rounding.
ORR, objective response rate; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; WT, wildtype; CN LOH, copy neutral loss of heterozygosity; mut, mutations; Mb, megabase;
§
MET focality can only be evaluated in MET-amplified cases; NE, not evaluable (no evaluable biomarker and/or not RECIST-evaluable)